Gabriella Szekely

Gabriella Szekely is the current Vice President of Research & Development for Combination Pharmaceutical Products at Glaukos. Gabriella has held this position since September of 2015. Prior to their current role, Gabriella served as the Vice President of Translational Sciences for Glaukos Corporation from 2012 to 2015. In this role, they provided senior leadership for the Translational Sciences department within Non-Clinical Development and oversaw a team of subject matter experts in various fields. Gabriella was also responsible for the development of key integrated messages and positions on assessments of dose-exposure-safety/efficacy in position papers and regulatory submissions. In 2015, they consolidated the nonclinical and clinical ADME-PK/pharmacology and bioanalytical sciences functions under one leadership for greater efficiency and to provide a seamless operation. Additionally, Gabriella served as a member of the Preclinical Safety Sciences scientific review board and provided guidance and input to the nonclinical project strategies, assessment, and mitigation of toxicology issues, safety concerns, non-clinical PK and toxicology as well as clinical PK and pharmacology study designs.

Gabriella Szekely earned a Ph.D. in Chemistry from Michigan State University and an MS in Chemistry from Debreceni Egyetem.

Gabriella Szekely reports to Thomas W. Burns, President & CEO. Gabriella Szekely works with Jay L. Katz - Chief Medical Officer, David S. Haffner - SVP, New Technologies, and Diane W. Biagianti - SVP & General Counsel.